FDA Grants Fast Track Status to Immunotherapy Candidate TRQ-1501 for Some Solid Tumors, Lymphomas
News
TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat ... Read more